MARKET WIREInvesting.com • 1d ago
H.C. Wainwright reiterates Cocrystal Pharma stock rating at buyInvesting.com report covering Cocrystal Pharma Inc. (COCP) market action, institutional positioning, and fundamental catalysts.
Why COCP Stock surged +6.53% Today — RQD Quant Desk Flash
$1.06 +6.53% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.07
Cocrystal Pharma Inc. (COCP) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $19.2M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on COCP Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is COCP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Cocrystal Pharma Inc. (NASDAQ: COCP) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $1.06 (+6.53% 1D, market cap $19.2M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, COCP ranks #575 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does COCP compare to AKTX and KYNB in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), COCP carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, AKTX (Akari Therapeutics plc ADS) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $18.8M) and KYNB (Kyntra Bio Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $18.5M). Among the 5-stock peer group, COCP leads on earnings multiple (N/A) while COCP leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for COCP?
▼
Per COCP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001412486), Cocrystal Pharma Inc. generated $25.3M in revenue (-49.6% YoY), -$8.8M in net income, and -$8.2M in free cash flow against $9.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.07 (+0.99%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR RQD RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-9.4% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for COCP)Realized 20D OHLCV Swing Band: ±12%
Deterministic 5-Pillar Attribution (36/100 Composite)
🔍 WHY COCP SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (28% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (22% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$1.08-13% Next Q
44
Q2 (-2Q)Grade D$0.94+4.3% Next Q
41
Q3 (-1Q)Grade E$0.98+8.2% Next Q
39
CurrentGrade D-$1.06-8.3% Hist 90D α
36
Trajectory: D (44) → D- (36)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a COCP Turnaround Squeeze
While COCP currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.10) and Max Pain ($1.11) forces dealer call-delta covering toward $2.13.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $COCP• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “COCP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why COCP Stock surged +6.53% Today — RQD Quant Desk Flash
Cocrystal Pharma Inc. (COCP) surged +6.53% to $1.06, trading at 24% of its 52-week range ($0.76 – $2.03). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 24% of its 52-week range ($0.76 – $2.03) with RSI-14 at 45.5 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12% around $1.06 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live COCP Headlines & Catalysts
MARKET WIREYahoo! Finance Canada • 1d ago
Cocrystal Pharma, Inc. (COCP) Seasonal Returns Chart - Yahoo FinanceYahoo! Finance Canada report covering Cocrystal Pharma Inc. (COCP) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
Cocrystal Pharma (NasdaqCM:COCP) Stock Forecast & Analyst PredictionsSimply Wall St report covering Cocrystal Pharma Inc. (COCP) market action, institutional positioning, and fundamental catalysts.
CATALYSThttps://www.siam.in/ • 1d ago
Cocrystal Pharma (COCP) Edges Lower to $1.06 as Shares Sit Between $1.01 Support and $1.11 Resistance - Bullish Pattern Stockshttps://www.siam.in/ report covering Cocrystal Pharma Inc. (COCP) market action, institutional positioning, and fundamental catalysts.
CATALYSTStocktwits • 1d ago
Why Did PFSA Stock Surge 150% Today?Stocktwits report covering Cocrystal Pharma Inc. (COCP) market action, institutional positioning, and fundamental catalysts.
CATALYSTUnisba Media • 1d ago
This Beaten Down Biotech Stock Has A Secret Billionaire Backer Ncis Sydney (nGext5ndB4)Unisba Media report covering Cocrystal Pharma Inc. (COCP) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo! Finance Canada • 1d ago
Daré Bioscience, Inc. (DARE) Stock Price, News, Quote & HistoryYahoo! Finance Canada report covering Cocrystal Pharma Inc. (COCP) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingKey • 2d ago
Top U.S. Stock Losers: Biggest Price DeclinesTradingKey report covering Cocrystal Pharma Inc. (COCP) market action, institutional positioning, and fundamental catalysts.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring COCP)
- ✓Walkthrough of COCP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
COCP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -19.08%▲ ASCENDING CHANNEL
2026-11-03O $0.98H $1.06L $0.98C $1.06VOL 62.8K
RES: $1.43SUP: $0.93SMA50: $1.10SMA200: $1.10
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
COCP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. -49.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on COCP today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for COCP. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for COCP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (COCP)
Health Care Rank #575 of 1015
⚔️ AKTX vs COCP Full Matrix →
1. Head-to-Head Health Care Peer Comparison (COCP vs. AKTX, KYNB, ACTU, QNTM)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Cocrystal Pharma Inc. (COCP) ranks #575 by composite RQD confidence (36/100, grade D-) and #831 by equity capitalization ($19.2M). Within this direct 5-issuer industry benchmark cohort, COCP leads on earnings valuation at N/A trailing P/E, while COCP leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. QNTM currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with COCP at 36/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| COCP
ACTIVE
Cocrystal Pharma Inc. | D- | 36/100 | — | — | -35.0% | +6.53% | $19.2M | Benchmark Subject |
| AKTX Akari Therapeutics plc ADS | D- | 37/100 | — | — | -35.0% | -4.85% | $18.8M | /aktx-vs-cocp → |
| KYNB Kyntra Bio Inc. | E | 32/100 | — | 91.4% | -35.0% | -2.41% | $18.5M | /kynb-vs-cocp → |
| ACTU Actuate Therapeutics Inc. | D- | 35/100 | — | — | -35.0% | +2.06% | $18.4M | /actu-vs-cocp → |
| QNTM Quantum Biopharma Ltd. Class B Subordinate Voting Shares | D | 46/100 | — | — | — | -5.04% | $20.2M | /qntm-vs-cocp → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001412486 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cocrystal Pharma Inc. (COCP) reported GAAP revenue of $25.3M (-49.6% vs. FY2024 revenue of $50.1M , and -51.4% cumulative change since FY2023) , GAAP net income of -$8.8M, operating cash flow of -$8.2M, and free cash flow of -$8.2M (+50.3% YoY). On the balance sheet, COCP closed FY2025 with $9.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $25.3M | -$8.8M | -$8.2M | -$8.2M | $9.7M | — |
| FY2024 (FY) | 2024-12-31 | $50.1M | -$17.5M | -$16.5M | -$16.5M | $13.5M | — |
| FY2023 (FY) | 2023-12-31 | $52.0M | -$18.0M | -$14.7M | -$14.7M | — | — |
3. COCP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs COCP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Cocrystal Pharma Inc. (NASDAQ: COCP) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $1.06 (+6.53% 1D, market cap $19.2M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, COCP ranks #575 in composite RQD confidence.
How does COCP compare to AKTX and KYNB in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), COCP carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, AKTX (Akari Therapeutics plc ADS) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $18.8M) and KYNB (Kyntra Bio Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $18.5M). Among the 5-stock peer group, COCP leads on earnings multiple (N/A) while COCP leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for COCP?
Per COCP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001412486), Cocrystal Pharma Inc. generated $25.3M in revenue (-49.6% YoY), -$8.8M in net income, and -$8.2M in free cash flow against $9.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is COCP trading relative to its 50-day, 200-day, and 52-week technical levels?
COCP last traded at $1.06 (+6.53% on volume of 14,928 shares), positioning the stock -3.64% below its 50-day simple moving average ($1.10) and -3.64% below its 200-day simple moving average ($1.10). Across its 52-week range of $0.76 to $2.03, COCP sits at the 23.6% percentile with a 14-day RSI of 45.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.0% ($1.00 to $1.19).
ROARABLE RATING BRIEF • RQD 36/100 (D-)
✓ SEC XBRL & RQD VERIFIED
COCP — Cocrystal Pharma Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Cocrystal Pharma Inc. (COCP) earns a live Roarable RQD composite score of 36/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $1.06 (+6.53% 1D, market capitalization $19.2M).
- Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
- Whale 13F & Options Flow (5/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (8/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Cocrystal Pharma Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. Reported revenue is — across the listed periods (), indicating no revenue recognized in those years. — for further business description.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Cocrystal Pharma Inc. (COCP) reported $25.3M in annual revenue (up from $50.1M in FY2024, -49.6% YoY) and -$8.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($52.0M revenue, -$18.0M net income) through FY2025, COCP scaled operating cash flow to -$8.2M and free cash flow to -$8.2M, backed by $9.7M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D- • RQD 36/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 5/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $0.76 – $2.03 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Upstream and downstream dependencies, sector correlations, and 2nd-order bottlenecks are therefore — Investors should note that the absence of mapped links means this brief cannot assess ripple effects from suppliers, partners, or sector peers.
- Key Question #1: Can COCP sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $25.3M and free cash flow of -$8.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is COCP's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
COCP Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Cocrystal Pharma Inc. (COCP) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Investing.com • 1d ago
H.C. Wainwright reiterates Cocrystal Pharma stock rating at buy Investing.com report covering Cocrystal Pharma Inc. (COCP) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago
Cocrystal Pharma, Inc. (COCP) Seasonal Returns Chart - Yahoo Finance Yahoo! Finance Canada report covering Cocrystal Pharma Inc. (COCP) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
Cocrystal Pharma (NasdaqCM:COCP) Stock Forecast & Analyst Predictions Simply Wall St report covering Cocrystal Pharma Inc. (COCP) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST https://www.siam.in/ • 1d ago
Cocrystal Pharma (COCP) Edges Lower to $1.06 as Shares Sit Between $1.01 Support and $1.11 Resistance - Bullish Pattern Stocks https://www.siam.in/ report covering Cocrystal Pharma Inc. (COCP) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Stocktwits • 1d ago
Why Did PFSA Stock Surge 150% Today? Stocktwits report covering Cocrystal Pharma Inc. (COCP) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Unisba Media • 1d ago
This Beaten Down Biotech Stock Has A Secret Billionaire Backer Ncis Sydney (nGext5ndB4) Unisba Media report covering Cocrystal Pharma Inc. (COCP) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago
Daré Bioscience, Inc. (DARE) Stock Price, News, Quote & History Yahoo! Finance Canada report covering Cocrystal Pharma Inc. (COCP) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingKey • 2d ago
Top U.S. Stock Losers: Biggest Price Declines TradingKey report covering Cocrystal Pharma Inc. (COCP) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
COCP Bull vs. Bear Conversation Board — What's Your Call at $1.06?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON COCP 🐻 33% BEARISH CONVICTION
AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH
🎯 Target: $1.29 (+29.0%)
📌 Pinned Debate Shares trade at $0.98 against a $0.76–$2.03 52-week range while the company holds $7.0M in reported cash and an Altman Z-Score of 2.5,
The street is overcomplicating Cocrystal Pharma Inc. (COCP). Shares trade at $0.98 against a $0.76–$2.03 52-week range while the company holds $7.0M in reported cash and an Altman Z-Score of 2.5, offering a low-priced entry with some balance-sheet cushion.. With an RQD score of 36/100 (D-) and Forensic Balance Sheet at 10/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $1.08.
RetailWhale_TX 🐂 BULL
Both sides have a point here — COCP's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH
🎯 Target: $0.86 (-14.0%)
Spot @ $1.00 With ROIC at -35%, FCF yield at 0%, zero reported revenue, and a Piotroski F-Score of 3/9, the company shows no cash-generation engine
I respect the product at Cocrystal Pharma Inc., but the stock at $1.00 is a different story. With ROIC at -35%, FCF yield at 0%, zero reported revenue, and a Piotroski F-Score of 3/9, the company shows no cash-generation engine and weak forensic strength.. FCF yield is 0.0% and RQD sits at 36/100 (D-) — why pay up here when you can wait for next quarter's numbers?